Wadzanai P. Samaneka

Harare, HA, Zimbabwe

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Pharmacokinetic modelling as a tool to assess TB treatment adherence: application to the REMEMBER study.

Pharmacokinetic modelling as a tool to assess TB treatment adherence: application to the REMEMBER study.

Journal: IJTLD open

Published: July 22, 2025

Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.

Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.

Journal: The lancet. HIV

Published: July 14, 2025

Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings.

Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: June 27, 2025

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

Journal: The Lancet. Infectious diseases

Published: April 17, 2025

Correction: Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.

Correction: Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.

Journal: AIDS research and therapy

Published: March 24, 2025

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.

Journal: Emerging infectious diseases

Published: March 02, 2025

Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.

Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.

Journal: Pharmacogenetics and genomics

Published: February 17, 2025

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Journal: Communications medicine

Published: February 14, 2025

Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial.

Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: February 07, 2025

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.

Journal: The lancet. HIV

Published: January 18, 2025

Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.

Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.

Journal: AIDS research and therapy

Published: October 17, 2024

Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.

Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: January 19, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026